Scientists find a way to block malaria parasite from making itself at home inside host blood cells; research opens up possibilities of new generation anti-malarial drugs
Two separate studies published last week announced breakthrough in the search for a cure for malaria. Working independently, the two teams of scientists from Australia and the US were able to block a mechanism used by the malaria parasite for its survival in the human host blood cells.
The parasite, Plasmodium falciparum, modifies the red blood cells in the human body to make them suitable for its habitation. For this it deposits proteins in the red blood cells through a gateway. The researchers have identified a way to block this gateway, which results in the death of the parasite.
The team that authored the first study, a collaboration between researchers from the Burnet Institute, Deakin University School of Medicine and Monash University, Australia, had earlier identified the gateway used for the export of proteins into the host cell, but did not possess evidence to show that it was the only such gateway. In this study, they succeeded in blocking the export of parasite proteins into the red blood cell, effectively killing the parasite. “We are now looking to better understand how the gateway is established, which will help with drug development in the future,” said Tania De Koning-Ward, associate professor at Deakin University Medical School.
The second study, authored by a team from Washington University School of Medicine in the US, targeted a protein called HSP101 or the heat-shock protein, so named because this family of proteins is activated when cells are overheated or stressed. They found that disabling HSP101 blocked all the malarial proteins from entering the red blood cells. The scientists think HSP101 readies malarial proteins for secretion through a pore that opens into the red blood cell. This preparation may involve unfolding the proteins into a linear form that allows them to more easily pass through the narrow pore.
Target for drug development
Both teams have expressed hope that these findings may lead to the development of a new generation of anti-malarial drugs that target the cell gateway to cure malaria. “We think this is a very promising target for drug development,” said Daniel Goldberg, MD, PhD, senior author of the study at the Washington University. “We’re a long way from getting a new drug, but in the short term we may look at screening a variety of compounds to see if they have the potential to block HSP101.”
The studies were published in the July 17 issue of Nature magazine.
Although there are currently treatments available for malaria, there has been an alarming increase in parasite resistance to these drugs. Partial resistance to artemisinin, recommended by WHO as the first-line treatment for uncomplicated malaria, has been seen in several Southeast Asian countries. According to the WHO, since no other treatment works as well as artemisinin-based therapies, if this resistance were to reach India or areas of sub-Saharan Africa, the consequences could be dire.
We are a voice to you; you have been a support to us. Together we build journalism that is independent, credible and fearless. You can further help us by making a donation. This will mean a lot for our ability to bring you news, perspectives and analysis from the ground so that we can make change together.
Comments are moderated and will be published only after the site moderator’s approval. Please use a genuine email ID and provide your name. Selected comments may also be used in the ‘Letters’ section of the Down To Earth print edition.